Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Crinetics Pharmaceuticals to Vertex Pharmaceuticals for $85.00 per share in cash. The investigation concerns whether Crinetics and its board violated federal securities laws or breached fiduciary duties by failing to obtain the best possible price, conduct a fair sales process, or disclose all material information. The firm notes that insiders may receive substantial benefits not available to ordinary shareholders and that the proposed transaction may contain terms limiting superior competing offers. Halper Sadeh may seek increased consideration or additional disclosures on behalf of shareholders.
Crinetics Pharmaceuticals IncInvestigation into sale process and potential undervaluation may lead to legal costs or deal disruption.
Vertex Pharmaceuticals Inc